-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 1st, Hualan, a vaccine subsidiary of Hualan Biotech, was listed on the Growth Enterprise Market of the Shenzhen Stock Exchange.
The stock did not perform well on the first day of listing and directly fell below the issue price
.
In addition to Hualan shares, other pharmaceutical companies that have recently broken down include Corfu Medical and Chengda Biotech
.
Among them, on October 25, Corfu Medical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market, and its share price opened 10.
89% lower on the first day of listing and broke
.
Industry analysts believe that in addition to the high price of the stock’s break, there are also deep-seated reasons such as its performance showing a downward trend and the core competitiveness defects caused by heavy marketing and light research and development.
On October 28, it occupied the domestic rabies vaccine all the year round.
Half of the National Cheng Kung University Biologics officially landed on the Science and Technology Innovation Board
.
However, this new stock suffered a tragic break on the first day of listing.
By the end of the market, half of the investors had chosen to flee, and Chengda Bio's market value had lost more than 12 billion yuan within a day
.
In fact, the break of A-shares has long been foreshadowed
.
According to statistics, a total of 396 companies have landed on the A-share market in 2020, but none of them broke on the first day of listing, and as of the end of the year, only 22 companies had fallen below the issue price
.
In the field of biomedicine, after September 2021, A shares ushered in a wave of breaks
.
First, the listing applications of the two biomedical companies, Haihe Pharmaceutical and Jikai Gene, were rejected by the China Securities Regulatory Commission before and after the listing, and then the number of companies accepted for listing on the Science and Technology Innovation Board changed significantly
.
According to statistics, in September, the number of companies accepted by the Sci-tech Innovation Board was 13; in October, only 4 companies were accepted by the Sci-Tech Innovation Board, and there were no biomedical companies
.
The author has learned that the number of pharmaceutical companies that have closed their doors on the science and technology innovation board is also increasing
.
According to statistics, since the launch of the Science and Technology Innovation Board, more than 90 companies have terminated their review and were denied listing
.
Among them, 24 are biomedical companies
.
Among them, only in the first ten months of 2021, 14 companies have already declared IPO failures
.
In the past, the Science and Technology Innovation Board, which allowed unprofitable companies to go public, became a new listing channel for pharmaceutical companies
.
According to statistics, in 2019, 18 pharmaceutical companies were listed on the A-share market, 15 of which were from the Sci-tech Innovation Board; in 2020, 42 pharmaceutical companies were listed on the Sci-Tech Innovation Board, accounting for over 60% of the shares
.
Today, it is quite different from the scene where a large number of biomedical companies poured in when the Sci-tech Innovation Board just opened
.
Analysis believes that there are many reasons for the break-up of A shares, including the accelerated pace of new stock issuance, the recent lack of market sentiment, and the continuous high-priced issuance caused by the blind praise of "unbeaten new shares" by all parties in the market
.
But the IPO break is ultimately due to the company's own problems, such as the poor fundamentals of IPOs
.
Behind the successive breaks of the pharmaceutical stocks, it can also be seen that the transformation of innovative achievements has become more and more of the focus of market consideration, rather than simply pursuing innovative ideas
.
However, in the field of biomedicine, while the market puts forward higher requirements for innovative companies, it also points out the direction of future innovation.
This is conducive to curbing the disorderly expansion of capital to a certain extent, and at the same time, it also improves listed companies’ Quality contributes to the healthy and orderly development of the pharmaceutical industry
.
The industry pointed out that the break of new shares means that the profit-making effect of new shares is weakened, and the income of new shares is gradually reduced.
The new future may no longer be the norm, and "breaking" will become the norm instead
.
The break of new stocks means that the market is becoming more rational, which will help guide market investors to correct value investment concepts
.
The stock did not perform well on the first day of listing and directly fell below the issue price
.
In addition to Hualan shares, other pharmaceutical companies that have recently broken down include Corfu Medical and Chengda Biotech
.
Among them, on October 25, Corfu Medical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market, and its share price opened 10.
89% lower on the first day of listing and broke
.
Industry analysts believe that in addition to the high price of the stock’s break, there are also deep-seated reasons such as its performance showing a downward trend and the core competitiveness defects caused by heavy marketing and light research and development.
On October 28, it occupied the domestic rabies vaccine all the year round.
Half of the National Cheng Kung University Biologics officially landed on the Science and Technology Innovation Board
.
However, this new stock suffered a tragic break on the first day of listing.
By the end of the market, half of the investors had chosen to flee, and Chengda Bio's market value had lost more than 12 billion yuan within a day
.
In fact, the break of A-shares has long been foreshadowed
.
According to statistics, a total of 396 companies have landed on the A-share market in 2020, but none of them broke on the first day of listing, and as of the end of the year, only 22 companies had fallen below the issue price
.
In the field of biomedicine, after September 2021, A shares ushered in a wave of breaks
.
First, the listing applications of the two biomedical companies, Haihe Pharmaceutical and Jikai Gene, were rejected by the China Securities Regulatory Commission before and after the listing, and then the number of companies accepted for listing on the Science and Technology Innovation Board changed significantly
.
According to statistics, in September, the number of companies accepted by the Sci-tech Innovation Board was 13; in October, only 4 companies were accepted by the Sci-Tech Innovation Board, and there were no biomedical companies
.
The author has learned that the number of pharmaceutical companies that have closed their doors on the science and technology innovation board is also increasing
.
According to statistics, since the launch of the Science and Technology Innovation Board, more than 90 companies have terminated their review and were denied listing
.
Among them, 24 are biomedical companies
.
Among them, only in the first ten months of 2021, 14 companies have already declared IPO failures
.
In the past, the Science and Technology Innovation Board, which allowed unprofitable companies to go public, became a new listing channel for pharmaceutical companies
.
According to statistics, in 2019, 18 pharmaceutical companies were listed on the A-share market, 15 of which were from the Sci-tech Innovation Board; in 2020, 42 pharmaceutical companies were listed on the Sci-Tech Innovation Board, accounting for over 60% of the shares
.
Today, it is quite different from the scene where a large number of biomedical companies poured in when the Sci-tech Innovation Board just opened
.
Analysis believes that there are many reasons for the break-up of A shares, including the accelerated pace of new stock issuance, the recent lack of market sentiment, and the continuous high-priced issuance caused by the blind praise of "unbeaten new shares" by all parties in the market
.
But the IPO break is ultimately due to the company's own problems, such as the poor fundamentals of IPOs
.
Behind the successive breaks of the pharmaceutical stocks, it can also be seen that the transformation of innovative achievements has become more and more of the focus of market consideration, rather than simply pursuing innovative ideas
.
However, in the field of biomedicine, while the market puts forward higher requirements for innovative companies, it also points out the direction of future innovation.
This is conducive to curbing the disorderly expansion of capital to a certain extent, and at the same time, it also improves listed companies’ Quality contributes to the healthy and orderly development of the pharmaceutical industry
.
The industry pointed out that the break of new shares means that the profit-making effect of new shares is weakened, and the income of new shares is gradually reduced.
The new future may no longer be the norm, and "breaking" will become the norm instead
.
The break of new stocks means that the market is becoming more rational, which will help guide market investors to correct value investment concepts
.
